Siemens Healthineers: The €49 Target That Investors Keep Ignoring

Siemens Healthineers stock near 52-week low at €34.75 despite 45% analyst upside. Guidance cut in May, European roadshow, €230M buyback, and planned Siemens AG stake reduction weigh.

The gap between what analysts believe Siemens Healthineers is worth and what the market is willing to pay has rarely been wider. With a consensus price target of €49.06 — implying more than 45% upside from current levels — strategists see a bargain. Yet the stock sits at €34.75, just a whisker above its 52-week low of €32.84, and the selling pressure has been relentless. Something has to give, but the market is showing no signs of trusting the narrative.

The root cause of the pessimism can be traced back to May, when management slashed its annual guidance. Revenue growth for fiscal 2026 is now expected to land between 4.5% and 5.0%, down from a prior range that reached 6%. Adjusted earnings per share were trimmed to a corridor of €2.20 to €2.30, and the shares promptly lost ground. Since the start of the year, the stock has shed 21.8%, stretching its 12-month decline to 24.77%.

To rebuild confidence, the executive team has embarked on a European roadshow, shuttling from Paris to Luxembourg to pitch institutional investors on the company’s long-term strengths. The pitch includes a restructuring of the struggling diagnostics division, where structural reforms in China’s healthcare system are crimping growth. Imaging and precision therapy, by contrast, remain solid performers. After the European leg, management plans to appear at healthcare conferences in the US and the UK. The next concrete test will come with the third-quarter earnings report, expected in July.

In parallel, a share buyback programme of up to €230 million kicked off in early June. The company can repurchase as many as 14 million shares through January 2027. Crucially, the bought-back stock is earmarked for employee compensation schemes, not cancellation — a signal of internal confidence that stops short of boosting per-share metrics for existing holders.

On the charts, the stock is attempting a technical recovery. Wednesday’s 3.21% bounce to €34.75 lifted the shares 5.82% above the year’s low, but the trend remains firmly negative. The 50-day moving average at €35.63 is the first hurdle; a clean break above that would brighten the short-term picture. Beyond that, resistance lies between €38.54 and the €40 mark, while the 200-day average at €42.08 underscores how far the medium-term trend has deteriorated — the stock trades more than 20% below it.

Momentum indicators are neutral for now. The 14-day relative strength index sits at 49.1, suggesting neither overbought nor oversold conditions. The annualised 30-day volatility of 29.2% reflects the edgy mood surrounding the healthcare sector, amplified by reports of investment cuts in Germany.

Adding to the uncertainty is the planned reduction of Siemens AG’s majority stake. The parent company is exploring a spin-off of 30% of Siemens Healthineers to its own shareholders as part of its “One Tech Company” strategy. A shareholder vote is tentatively scheduled for February 2027. Such a move inevitably creates overhang, as investors weigh the implications of a changed ownership structure.

For now, the market is voting with its feet. The average analyst EPS estimate of €2.25 for 2026 lands squarely inside management’s target range, yet the share price refuses to close the gap. Either the analysts are right and the market is overly pessimistic, or the market sees risks the sell-side has yet to price in. The next quarterly numbers will offer a clue — and the €230 million buyback gives management some ammunition to defend the floor near €32.84, the line that separates a recovery from a deeper rout.